patient_id stringlengths 6 6 | age int64 20 85 | gender stringclasses 3
values | ethnicity stringclasses 6
values | height_cm int64 151 195 | weight_kg int64 50 144 | bmi float64 15.3 57.7 | smoking_status stringclasses 3
values | alcohol_use stringclasses 2
values | primary_condition stringclasses 10
values | secondary_conditions stringlengths 4 69 ⌀ | current_medications stringlengths 9 44 | prior_treatments stringlengths 16 48 ⌀ | enrollment_date stringdate 2021-02-09 00:00:00 2024-06-30 00:00:00 | trial_arm stringclasses 4
values | adverse_events stringlengths 11 40 ⌀ | adverse_event_severity stringclasses 2
values | treatment_response stringclasses 3
values | dropout_reason stringclasses 5
values | lab_results stringlengths 66 91 | notes stringlengths 62 107 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PT0001 | 53 | Male | White | 158 | 144 | 57.7 | Non-smoker | Moderate | Epilepsy | null | topiramate; levetiracetam; carbamazepine | null | 2022-03-24 | Placebo | null | null | Non-responder | Adverse Event | {"Drug_Level": 71.3, "ALT": 63, "CBC_WBC": 4.8, "Sodium": 136, "Hemoglobin": 14.7} | Patient tolerating Placebo well with Non-responder noted at week 12; monitoring labs closely. |
PT0002 | 72 | Male | White | 159 | 77 | 30.5 | Current | null | Chronic Kidney Disease | null | erythropoietin; furosemide | Surgical intervention | 2022-06-26 | Active Comparator | null | null | Non-responder | Other | {"Creatinine": 4.34, "GFR": 45, "Potassium": 4.8, "Phosphorus": 6.3, "Hemoglobin": 11.4} | No adverse events reported; labs within normal range at most recent visit. |
PT0003 | 23 | Female | Black | 168 | 60 | 21.3 | Current | Heavy | Heart Failure | Type 2 Diabetes; Chronic Kidney Disease; Anemia | furosemide; lisinopril | Physical therapy | 2022-07-01 | High Dose | null | null | Responder | Adverse Event | {"BNP": 2337, "Creatinine": 2.43, "Sodium": 130, "Potassium": 4.4, "EF_pct": 23} | Responder at interim analysis; continuing to next study phase. |
PT0004 | 25 | Male | White | 152 | 90 | 39 | Non-smoker | null | Rheumatoid Arthritis | Cardiovascular Disease; Anemia | etanercept; leflunomide | null | 2022-06-27 | Placebo | null | null | Non-responder | Lack of Efficacy | {"CRP": 19.6, "ESR": 89, "RF": 214, "Hemoglobin": 10.7, "WBC": 12.0} | Stable on current regimen; Non-responder confirmed at 6-month follow-up. |
PT0005 | 24 | Male | Hispanic | 159 | 130 | 51.4 | Non-smoker | Moderate | Heart Failure | null | spironolactone; digoxin | Dietary counseling; Lifestyle modification | 2021-08-23 | High Dose | null | null | Responder | Adverse Event | {"BNP": 606, "Creatinine": 1.52, "Sodium": 130, "Potassium": 4.4, "EF_pct": 45} | Mild no adverse events reported but manageable; patient prefers to continue. |
PT0006 | 82 | Female | Asian | 190 | 88 | 24.4 | Current | Moderate | Hypothyroidism | Depression | levothyroxine; liothyronine | Dietary counseling; Previous pharmacotherapy | 2021-02-09 | Placebo | null | null | Partial Responder | Lack of Efficacy | {"TSH": 15.4, "Free_T4": 0.52, "LDL": 245, "Hemoglobin": 13.7, "CK": 93} | Referred back to primary care physician following no adverse events; study participation ended. |
PT0007 | 34 | Female | White | 180 | 120 | 37 | Non-smoker | Moderate | COPD | Osteoporosis; Cachexia; Lung Cancer Risk | roflumilast; fluticasone | Surgical intervention | 2023-07-14 | Placebo | null | null | Non-responder | Completed | {"FEV1_pct": 34, "SpO2": 89, "PaCO2": 38, "CRP": 3.1, "Hemoglobin": 15.0} | Dropped out due to Completed; final labs obtained prior to discontinuation. |
PT0008 | 60 | Male | White | 165 | 85 | 31.2 | Former | null | Type 2 Diabetes | Peripheral Neuropathy | empagliflozin; glipizide; insulin glargine | Physical therapy | 2021-07-13 | Placebo | null | null | Non-responder | Completed | {"A1C": 9.8, "LDL": 166, "Creatinine": 1.61, "Glucose_fasting": 275, "HDL": 36} | Patient tolerating Placebo well with Non-responder noted at week 12; monitoring labs closely. |
PT0009 | 31 | Male | White | 162 | 118 | 45 | Non-smoker | Moderate | Asthma | Sleep Apnea; Allergic Rhinitis | salmeterol | Lifestyle modification; Surgical intervention | 2024-01-13 | Active Comparator | null | null | Partial Responder | Lost to Follow-up | {"FEV1_pct": 55, "FVC": 3.4, "FeNO": 76, "Eosinophils": 0.4, "IgE": 460} | Patient tolerating Active Comparator well with Partial Responder noted at week 12; monitoring labs closely. |
PT0010 | 67 | Male | White | 179 | 86 | 26.8 | Non-smoker | Heavy | Hypertension | Type 2 Diabetes; Hyperlipidemia; Left Ventricular Hypertrophy | lisinopril | Surgical intervention; Lifestyle modification | 2022-10-05 | Placebo | null | null | Non-responder | Lost to Follow-up | {"Systolic_BP": 150, "Diastolic_BP": 88, "Creatinine": 2.43, "Potassium": 3.4, "LDL": 127} | Reports no adverse events since initiation; dose adjustment under consideration. |
PT0011 | 48 | Female | White | 186 | 81 | 23.4 | Former | null | Heart Failure | null | digoxin; lisinopril | Physical therapy | 2022-10-06 | Placebo | null | null | Non-responder | Completed | {"BNP": 1445, "Creatinine": 2.85, "Sodium": 142, "Potassium": 3.2, "EF_pct": 29} | Patient experiencing no adverse events; dose held pending investigator review. |
PT0012 | 27 | Other | White | 182 | 83 | 25.1 | Non-smoker | null | Hypothyroidism | null | liothyronine | Physical therapy | 2023-06-17 | Active Comparator | null | null | Non-responder | Other | {"TSH": 34.26, "Free_T4": 0.4, "LDL": 241, "Hemoglobin": 10.5, "CK": 389} | Reports no adverse events since initiation; dose adjustment under consideration. |
PT0013 | 32 | Male | Hispanic | 185 | 69 | 20.2 | Non-smoker | Moderate | Hypothyroidism | Depression; Obesity | liothyronine; levothyroxine | null | 2023-05-18 | Active Comparator | Insomnia; Weight Loss | Mild | Responder | Adverse Event | {"TSH": 30.02, "Free_T4": 0.46, "LDL": 138, "Hemoglobin": 11.7, "CK": 477} | No adverse events reported; labs within normal range at most recent visit. |
PT0014 | 34 | Male | White | 173 | 55 | 18.4 | Current | null | Heart Failure | Hypertension | digoxin; spironolactone | Physical therapy; Surgical intervention | 2021-11-29 | Active Comparator | null | null | Partial Responder | Completed | {"BNP": 1510, "Creatinine": 2.54, "Sodium": 134, "Potassium": 5.4, "EF_pct": 42} | Dropped out due to Completed; final labs obtained prior to discontinuation. |
PT0015 | 31 | Female | White | 152 | 110 | 47.6 | Non-smoker | Moderate | Rheumatoid Arthritis | Anemia; Cardiovascular Disease; Osteoporosis | methotrexate | Physical therapy; Previous pharmacotherapy | 2022-11-04 | Low Dose | Bone Marrow Suppression; GI Bleeding | Mild | Partial Responder | Completed | {"CRP": 42.3, "ESR": 29, "RF": 143, "Hemoglobin": 9.6, "WBC": 11.7} | Mild Bone Marrow Suppression reported but manageable; patient prefers to continue. |
PT0016 | 62 | Female | Black | 170 | 105 | 36.3 | Former | Moderate | Type 2 Diabetes | Peripheral Neuropathy; Obesity; Non-alcoholic Fatty Liver Disease | empagliflozin | null | 2023-12-01 | Active Comparator | null | null | Partial Responder | Lack of Efficacy | {"A1C": 9.5, "LDL": 126, "Creatinine": 1.3, "Glucose_fasting": 280, "HDL": 51} | Patient experiencing no adverse events; dose held pending investigator review. |
PT0017 | 56 | Female | White | 192 | 102 | 27.7 | Non-smoker | Moderate | Major Depressive Disorder | Insomnia | bupropion; escitalopram | Surgical intervention; Dietary counseling | 2023-04-12 | High Dose | Sexual Dysfunction; Nausea | Moderate | Non-responder | Completed | {"TSH": 3.76, "Sodium": 142, "Vitamin_D": 25, "CBC_WBC": 7.6, "ALT": 31} | Reports Sexual Dysfunction since initiation; dose adjustment under consideration. |
PT0018 | 60 | Female | White | 165 | 136 | 50 | Non-smoker | Moderate | Rheumatoid Arthritis | Osteoporosis | hydroxychloroquine | Surgical intervention | 2021-05-30 | Low Dose | null | null | Non-responder | Adverse Event | {"CRP": 17.6, "ESR": 66, "RF": 134, "Hemoglobin": 9.4, "WBC": 9.3} | Reports no adverse events since initiation; dose adjustment under consideration. |
PT0019 | 84 | Male | White | 185 | 81 | 23.7 | Current | null | Chronic Kidney Disease | Hyperphosphatemia | sevelamer; furosemide; calcium carbonate | Surgical intervention; Previous pharmacotherapy | 2024-01-28 | Low Dose | Hypertension Worsening; Fluid Overload | Moderate | Partial Responder | Completed | {"Creatinine": 7.01, "GFR": 41, "Potassium": 5.8, "Phosphorus": 4.7, "Hemoglobin": 7.4} | Mild Hypertension Worsening reported but manageable; patient prefers to continue. |
PT0020 | 28 | Male | White | 164 | 99 | 36.8 | Former | Moderate | Rheumatoid Arthritis | null | etanercept; prednisone | Previous pharmacotherapy; Surgical intervention | 2021-05-08 | Placebo | null | null | Partial Responder | Completed | {"CRP": 31.5, "ESR": 88, "RF": 204, "Hemoglobin": 11.4, "WBC": 11.5} | Mild no adverse events reported but manageable; patient prefers to continue. |
PT0021 | 71 | Female | White | 184 | 127 | 37.5 | Current | Moderate | Chronic Kidney Disease | Hyperphosphatemia; Secondary Hyperparathyroidism | bicarbonate | Previous pharmacotherapy | 2021-12-05 | Active Comparator | null | null | Partial Responder | Completed | {"Creatinine": 7.88, "GFR": 47, "Potassium": 5.6, "Phosphorus": 3.6, "Hemoglobin": 10.2} | Stable on current regimen; Partial Responder confirmed at 6-month follow-up. |
PT0022 | 51 | Male | White | 163 | 108 | 40.6 | Non-smoker | Moderate | COPD | Lung Cancer Risk; Depression; Osteoporosis | roflumilast | null | 2024-01-10 | Placebo | null | null | Non-responder | Completed | {"FEV1_pct": 61, "SpO2": 83, "PaCO2": 39, "CRP": 28.5, "Hemoglobin": 11.6} | Patient tolerating Placebo well with Non-responder noted at week 12; monitoring labs closely. |
PT0023 | 78 | Male | Black | 186 | 77 | 22.3 | Non-smoker | null | Epilepsy | Anxiety Disorder; Cognitive Impairment | levetiracetam; valproate; topiramate | null | 2024-03-31 | Placebo | null | null | Non-responder | Other | {"Drug_Level": 42.1, "ALT": 35, "CBC_WBC": 3.6, "Sodium": 135, "Hemoglobin": 9.7} | Mild no adverse events reported but manageable; patient prefers to continue. |
PT0024 | 33 | Female | Hispanic | 186 | 55 | 15.9 | Non-smoker | Moderate | COPD | Cardiovascular Disease; Lung Cancer Risk | roflumilast | Lifestyle modification | 2023-06-07 | Active Comparator | null | null | Partial Responder | Adverse Event | {"FEV1_pct": 47, "SpO2": 87, "PaCO2": 55, "CRP": 18.9, "Hemoglobin": 17.4} | Referred back to primary care physician following no adverse events; study participation ended. |
PT0025 | 52 | Female | White | 165 | 61 | 22.4 | Non-smoker | Moderate | Asthma | Sleep Apnea; Obesity; Allergic Rhinitis | montelukast; albuterol | Physical therapy | 2022-12-28 | Active Comparator | Bronchospasm; Oral Candidiasis | Mild | Responder | Completed | {"FEV1_pct": 71, "FVC": 3.7, "FeNO": 45, "Eosinophils": 1.07, "IgE": 711} | Referred back to primary care physician following Bronchospasm; study participation ended. |
PT0026 | 55 | Male | White | 194 | 81 | 21.5 | Non-smoker | Moderate | Asthma | GERD; Obesity; Sleep Apnea | salmeterol; montelukast | Dietary counseling | 2022-04-18 | Placebo | null | null | Responder | Completed | {"FEV1_pct": 93, "FVC": 4.4, "FeNO": 39, "Eosinophils": 0.4, "IgE": 545} | Mild no adverse events reported but manageable; patient prefers to continue. |
PT0027 | 85 | Female | White | 156 | 74 | 30.4 | Non-smoker | null | Chronic Kidney Disease | Hypertension; Type 2 Diabetes | erythropoietin; sevelamer | Dietary counseling; Physical therapy | 2023-10-03 | Placebo | Hypertension Worsening; Anemia Worsening | Mild | Non-responder | Completed | {"Creatinine": 8.11, "GFR": 40, "Potassium": 4.3, "Phosphorus": 3.8, "Hemoglobin": 9.5} | Patient experiencing Hypertension Worsening; dose held pending investigator review. |
PT0028 | 37 | Male | Hispanic | 169 | 60 | 21 | Current | null | Epilepsy | Anxiety Disorder; Cognitive Impairment; Sleep Disorder | topiramate; lamotrigine | Previous pharmacotherapy; Dietary counseling | 2024-03-10 | High Dose | null | null | Non-responder | Other | {"Drug_Level": 23.9, "ALT": 37, "CBC_WBC": 5.1, "Sodium": 130, "Hemoglobin": 10.1} | Stable on current regimen; Non-responder confirmed at 6-month follow-up. |
PT0029 | 70 | Male | White | 188 | 110 | 31.1 | Non-smoker | null | Heart Failure | Chronic Kidney Disease; Hypertension | furosemide; lisinopril; spironolactone | Physical therapy; Previous pharmacotherapy | 2021-08-24 | High Dose | null | null | Partial Responder | Lost to Follow-up | {"BNP": 442, "Creatinine": 1.03, "Sodium": 140, "Potassium": 3.9, "EF_pct": 38} | Patient experiencing no adverse events; dose held pending investigator review. |
PT0030 | 77 | Male | Black | 194 | 101 | 26.8 | Current | Moderate | Hypothyroidism | Anemia; Hyperlipidemia; Obesity | liothyronine | Dietary counseling; Surgical intervention | 2021-02-22 | Placebo | null | null | Partial Responder | Completed | {"TSH": 47.76, "Free_T4": 0.9, "LDL": 168, "Hemoglobin": 11.9, "CK": 440} | Stable on current regimen; Partial Responder confirmed at 6-month follow-up. |
PT0031 | 53 | Female | White | 187 | 105 | 30 | Former | Moderate | Asthma | null | montelukast; salmeterol | Dietary counseling | 2021-08-03 | Active Comparator | Tremor; Tachycardia | Moderate | Non-responder | Completed | {"FEV1_pct": 65, "FVC": 2.9, "FeNO": 29, "Eosinophils": 1.46, "IgE": 463} | Non-responder at interim analysis; continuing to next study phase. |
PT0032 | 77 | Male | White | 162 | 116 | 44.2 | Non-smoker | Moderate | COPD | Cardiovascular Disease; Osteoporosis; Depression | salmeterol; fluticasone; azithromycin | Previous pharmacotherapy; Lifestyle modification | 2021-03-01 | Active Comparator | null | null | Responder | Completed | {"FEV1_pct": 55, "SpO2": 82, "PaCO2": 64, "CRP": 3.7, "Hemoglobin": 17.9} | Reports no adverse events since initiation; dose adjustment under consideration. |
PT0033 | 37 | Male | White | 195 | 87 | 22.9 | Non-smoker | null | Asthma | Sleep Apnea; Allergic Rhinitis; Obesity | albuterol; salmeterol; fluticasone | Surgical intervention; Physical therapy | 2021-05-23 | Low Dose | null | null | Non-responder | Lost to Follow-up | {"FEV1_pct": 77, "FVC": 2.9, "FeNO": 15, "Eosinophils": 0.5, "IgE": 355} | Patient experiencing no adverse events; dose held pending investigator review. |
PT0034 | 37 | Female | White | 180 | 94 | 29 | Non-smoker | Moderate | Heart Failure | Chronic Kidney Disease; Type 2 Diabetes; Hypertension | furosemide; spironolactone; carvedilol | Lifestyle modification | 2022-10-14 | High Dose | null | null | Partial Responder | Completed | {"BNP": 2868, "Creatinine": 2.56, "Sodium": 138, "Potassium": 5.9, "EF_pct": 30} | Patient tolerating High Dose well with Partial Responder noted at week 12; monitoring labs closely. |
PT0035 | 60 | Female | Hispanic | 178 | 62 | 19.6 | Non-smoker | Moderate | Hypertension | Left Ventricular Hypertrophy | amlodipine; lisinopril; losartan | Dietary counseling | 2024-06-30 | High Dose | null | null | Partial Responder | Lost to Follow-up | {"Systolic_BP": 198, "Diastolic_BP": 109, "Creatinine": 2.42, "Potassium": 4.8, "LDL": 204} | Partial Responder at interim analysis; continuing to next study phase. |
PT0036 | 54 | Male | Other | 155 | 105 | 43.7 | Current | Moderate | Type 2 Diabetes | null | glipizide; sitagliptin | null | 2021-04-05 | Low Dose | Weight Gain; Edema | Mild | Non-responder | Completed | {"A1C": 10.1, "LDL": 101, "Creatinine": 0.95, "Glucose_fasting": 266, "HDL": 54} | Patient experiencing Weight Gain; dose held pending investigator review. |
PT0037 | 36 | Female | White | 190 | 82 | 22.7 | Non-smoker | Moderate | Epilepsy | Cognitive Impairment; Sleep Disorder; Depression | topiramate | Surgical intervention | 2022-09-05 | High Dose | Stevens-Johnson Syndrome; Weight Gain | Mild | Responder | Completed | {"Drug_Level": 26.8, "ALT": 83, "CBC_WBC": 5.9, "Sodium": 137, "Hemoglobin": 15.9} | Mild Stevens-Johnson Syndrome reported but manageable; patient prefers to continue. |
PT0038 | 68 | Female | White | 186 | 137 | 39.6 | Former | Heavy | Type 2 Diabetes | Hyperlipidemia; Obesity; Peripheral Neuropathy | glipizide; insulin glargine | Dietary counseling; Physical therapy | 2021-07-18 | Active Comparator | null | null | Responder | Completed | {"A1C": 9.1, "LDL": 173, "Creatinine": 0.88, "Glucose_fasting": 185, "HDL": 50} | Patient compliant with study medication; Responder at week 8 assessment. |
PT0039 | 64 | Male | White | 167 | 71 | 25.5 | Non-smoker | Moderate | Hypertension | Chronic Kidney Disease; Left Ventricular Hypertrophy; Type 2 Diabetes | hydrochlorothiazide | null | 2021-10-16 | Active Comparator | Fatigue; Edema | Mild | Responder | Completed | {"Systolic_BP": 145, "Diastolic_BP": 114, "Creatinine": 1.36, "Potassium": 5.1, "LDL": 147} | Patient experiencing Fatigue; dose held pending investigator review. |
PT0040 | 65 | Female | White | 164 | 110 | 40.9 | Non-smoker | Heavy | Major Depressive Disorder | Insomnia; Chronic Pain | bupropion | Dietary counseling; Previous pharmacotherapy | 2021-08-27 | Placebo | null | null | Non-responder | Completed | {"TSH": 1.14, "Sodium": 140, "Vitamin_D": 20, "CBC_WBC": 6.7, "ALT": 57} | Non-responder at interim analysis; continuing to next study phase. |
PT0041 | 37 | Female | Hispanic | 191 | 62 | 17 | Current | Moderate | Asthma | Allergic Rhinitis; GERD | albuterol; salmeterol | Physical therapy | 2023-01-13 | Placebo | null | null | Non-responder | Other | {"FEV1_pct": 67, "FVC": 2.2, "FeNO": 50, "Eosinophils": 0.37, "IgE": 175} | Referred back to primary care physician following no adverse events; study participation ended. |
PT0042 | 20 | Male | White | 171 | 81 | 27.7 | Current | Moderate | Type 2 Diabetes | Hypertension | glipizide; insulin glargine; metformin | Physical therapy | 2024-05-05 | Placebo | null | null | Responder | Completed | {"A1C": 7.6, "LDL": 102, "Creatinine": 0.85, "Glucose_fasting": 116, "HDL": 38} | Patient tolerating Placebo well with Responder noted at week 12; monitoring labs closely. |
PT0043 | 59 | Female | White | 166 | 56 | 20.3 | Non-smoker | Moderate | Major Depressive Disorder | null | sertraline; bupropion; escitalopram | Surgical intervention | 2024-04-30 | Placebo | null | null | Partial Responder | Completed | {"TSH": 6.35, "Sodium": 145, "Vitamin_D": 54, "CBC_WBC": 7.7, "ALT": 68} | Patient tolerating Placebo well with Partial Responder noted at week 12; monitoring labs closely. |
PT0044 | 69 | Male | White | 156 | 112 | 46 | Former | Moderate | Type 2 Diabetes | null | insulin glargine; glipizide | null | 2021-09-16 | Low Dose | null | null | Non-responder | Completed | {"A1C": 11.0, "LDL": 147, "Creatinine": 1.11, "Glucose_fasting": 239, "HDL": 68} | Patient compliant with study medication; Non-responder at week 8 assessment. |
PT0045 | 45 | Female | White | 164 | 102 | 37.9 | Non-smoker | Moderate | Type 2 Diabetes | Hypertension; Hyperlipidemia; Obesity | sitagliptin; insulin glargine | null | 2023-08-30 | Placebo | null | null | Responder | Completed | {"A1C": 9.8, "LDL": 183, "Creatinine": 0.88, "Glucose_fasting": 125, "HDL": 67} | Responder at interim analysis; continuing to next study phase. |
PT0046 | 70 | Female | White | 192 | 104 | 28.2 | Current | Moderate | Heart Failure | Anemia; Type 2 Diabetes | carvedilol; furosemide | null | 2023-09-15 | Placebo | Hypotension; Hyperkalemia | Moderate | Partial Responder | Lost to Follow-up | {"BNP": 2696, "Creatinine": 2.19, "Sodium": 138, "Potassium": 4.7, "EF_pct": 34} | Mild Hypotension reported but manageable; patient prefers to continue. |
PT0047 | 57 | Male | Asian | 172 | 50 | 16.9 | Non-smoker | null | Type 2 Diabetes | Hypertension; Obesity; Hyperlipidemia | metformin; insulin glargine; sitagliptin | Physical therapy; Previous pharmacotherapy | 2023-05-10 | Low Dose | Weight Gain; Hypoglycemia | Moderate | Responder | Lack of Efficacy | {"A1C": 6.7, "LDL": 90, "Creatinine": 1.08, "Glucose_fasting": 279, "HDL": 57} | Referred back to primary care physician following Weight Gain; study participation ended. |
PT0048 | 45 | Male | Hispanic | 157 | 94 | 38.1 | Non-smoker | null | Epilepsy | Cognitive Impairment; Depression; Sleep Disorder | carbamazepine; levetiracetam | null | 2022-02-23 | Low Dose | Weight Gain | Mild | Responder | Completed | {"Drug_Level": 45.3, "ALT": 26, "CBC_WBC": 6.0, "Sodium": 135, "Hemoglobin": 12.5} | No adverse events reported; labs within normal range at most recent visit. |
PT0049 | 23 | Female | White | 179 | 59 | 18.4 | Current | Moderate | Type 2 Diabetes | Non-alcoholic Fatty Liver Disease; Hyperlipidemia; Hypertension | metformin; sitagliptin | null | 2024-06-19 | Low Dose | null | null | Non-responder | Completed | {"A1C": 7.0, "LDL": 135, "Creatinine": 1.52, "Glucose_fasting": 244, "HDL": 35} | Patient compliant with study medication; Non-responder at week 8 assessment. |
PT0050 | 46 | Female | White | 160 | 59 | 23 | Non-smoker | null | COPD | Lung Cancer Risk | salmeterol; azithromycin | null | 2021-10-27 | Low Dose | Oral Candidiasis | Mild | Partial Responder | Completed | {"FEV1_pct": 68, "SpO2": 96, "PaCO2": 58, "CRP": 26.1, "Hemoglobin": 15.0} | Stable on current regimen; Partial Responder confirmed at 6-month follow-up. |
PT0051 | 56 | Male | Hispanic | 187 | 57 | 16.3 | Non-smoker | null | Asthma | Sleep Apnea; Allergic Rhinitis; GERD | montelukast; fluticasone | Lifestyle modification; Previous pharmacotherapy | 2023-08-06 | High Dose | null | null | Non-responder | Completed | {"FEV1_pct": 81, "FVC": 4.3, "FeNO": 56, "Eosinophils": 0.95, "IgE": 563} | Stable on current regimen; Non-responder confirmed at 6-month follow-up. |
PT0052 | 61 | Male | Mixed | 155 | 114 | 47.5 | Former | null | Hypothyroidism | Anemia; Depression; Cardiovascular Disease | liothyronine; levothyroxine | Dietary counseling | 2024-05-09 | Placebo | null | null | Non-responder | Completed | {"TSH": 29.89, "Free_T4": 0.59, "LDL": 164, "Hemoglobin": 12.6, "CK": 386} | Patient experiencing no adverse events; dose held pending investigator review. |
PT0053 | 36 | Male | Asian | 169 | 133 | 46.6 | Former | null | COPD | null | azithromycin; roflumilast | Dietary counseling; Physical therapy | 2023-12-15 | Placebo | null | null | Non-responder | Completed | {"FEV1_pct": 39, "SpO2": 87, "PaCO2": 51, "CRP": 10.9, "Hemoglobin": 16.1} | Dropped out due to Completed; final labs obtained prior to discontinuation. |
PT0054 | 27 | Male | White | 156 | 114 | 46.8 | Former | Moderate | Rheumatoid Arthritis | null | prednisone; hydroxychloroquine; leflunomide | Physical therapy | 2021-11-29 | Placebo | null | null | Non-responder | Lost to Follow-up | {"CRP": 32.6, "ESR": 20, "RF": 220, "Hemoglobin": 10.7, "WBC": 9.6} | Referred back to primary care physician following no adverse events; study participation ended. |
PT0055 | 75 | Female | White | 165 | 89 | 32.7 | Current | Moderate | Epilepsy | Cognitive Impairment | carbamazepine; topiramate; valproate | Previous pharmacotherapy | 2023-10-27 | High Dose | null | null | Partial Responder | Lack of Efficacy | {"Drug_Level": 17.3, "ALT": 42, "CBC_WBC": 3.4, "Sodium": 143, "Hemoglobin": 15.1} | Partial Responder at interim analysis; continuing to next study phase. |
PT0056 | 84 | Female | Hispanic | 168 | 60 | 21.3 | Former | null | Hypothyroidism | Anemia | levothyroxine | Dietary counseling | 2021-02-24 | Low Dose | null | null | Non-responder | Completed | {"TSH": 8.21, "Free_T4": 0.51, "LDL": 181, "Hemoglobin": 13.7, "CK": 479} | No adverse events reported; labs within normal range at most recent visit. |
PT0057 | 54 | Male | Asian | 180 | 139 | 42.9 | Current | Moderate | Chronic Kidney Disease | Hyperphosphatemia; Hypertension; Secondary Hyperparathyroidism | furosemide | null | 2021-11-03 | High Dose | null | null | Responder | Completed | {"Creatinine": 3.73, "GFR": 29, "Potassium": 4.3, "Phosphorus": 4.6, "Hemoglobin": 10.2} | Patient experiencing no adverse events; dose held pending investigator review. |
PT0058 | 81 | Male | White | 151 | 130 | 57 | Non-smoker | null | Asthma | GERD | fluticasone; montelukast | null | 2024-03-14 | Low Dose | null | null | Responder | Other | {"FEV1_pct": 49, "FVC": 5.3, "FeNO": 84, "Eosinophils": 0.81, "IgE": 569} | Responder at interim analysis; continuing to next study phase. |
PT0059 | 23 | Female | Black | 173 | 82 | 27.4 | Former | null | Type 2 Diabetes | null | glipizide; metformin | Dietary counseling; Physical therapy | 2021-04-01 | Low Dose | null | null | Non-responder | Lost to Follow-up | {"A1C": 9.6, "LDL": 169, "Creatinine": 1.37, "Glucose_fasting": 156, "HDL": 38} | Reports no adverse events since initiation; dose adjustment under consideration. |
PT0060 | 22 | Female | White | 152 | 75 | 32.5 | Current | null | Chronic Kidney Disease | Secondary Hyperparathyroidism; Hyperphosphatemia | bicarbonate; furosemide; erythropoietin | Physical therapy; Dietary counseling | 2023-01-02 | Active Comparator | Fluid Overload; Nausea | Moderate | Responder | Completed | {"Creatinine": 4.75, "GFR": 34, "Potassium": 4.9, "Phosphorus": 4.3, "Hemoglobin": 10.5} | No adverse events reported; labs within normal range at most recent visit. |
PT0061 | 28 | Female | Black | 155 | 105 | 43.7 | Former | Moderate | Hypothyroidism | Obesity; Hyperlipidemia | liothyronine | Dietary counseling; Surgical intervention | 2023-07-03 | High Dose | Weight Loss; Bone Loss | Mild | Partial Responder | Completed | {"TSH": 49.92, "Free_T4": 0.54, "LDL": 114, "Hemoglobin": 9.4, "CK": 376} | Patient compliant with study medication; Partial Responder at week 8 assessment. |
PT0062 | 38 | Female | Asian | 159 | 127 | 50.2 | Former | Moderate | Major Depressive Disorder | Anxiety Disorder | venlafaxine | Previous pharmacotherapy | 2024-03-07 | Placebo | null | null | Non-responder | Completed | {"TSH": 3.77, "Sodium": 133, "Vitamin_D": 48, "CBC_WBC": 5.0, "ALT": 56} | Patient compliant with study medication; Non-responder at week 8 assessment. |
PT0063 | 32 | Male | White | 161 | 113 | 43.6 | Non-smoker | Heavy | Major Depressive Disorder | null | venlafaxine; bupropion | null | 2024-06-07 | Low Dose | null | null | Non-responder | Completed | {"TSH": 6.88, "Sodium": 139, "Vitamin_D": 23, "CBC_WBC": 10.3, "ALT": 66} | Reports no adverse events since initiation; dose adjustment under consideration. |
PT0064 | 58 | Female | Black | 195 | 58 | 15.3 | Non-smoker | null | COPD | Osteoporosis; Cachexia | azithromycin; salmeterol | null | 2022-02-16 | Active Comparator | Oral Candidiasis; Tachycardia | Moderate | Responder | Lack of Efficacy | {"FEV1_pct": 55, "SpO2": 86, "PaCO2": 43, "CRP": 2.9, "Hemoglobin": 13.2} | Referred back to primary care physician following Oral Candidiasis; study participation ended. |
PT0065 | 27 | Female | White | 170 | 132 | 45.7 | Non-smoker | Moderate | Heart Failure | Atrial Fibrillation; Anemia | spironolactone | Lifestyle modification; Surgical intervention | 2023-11-28 | Placebo | null | null | Non-responder | Adverse Event | {"BNP": 1567, "Creatinine": 2.89, "Sodium": 136, "Potassium": 5.7, "EF_pct": 42} | Reports no adverse events since initiation; dose adjustment under consideration. |
PT0066 | 53 | Female | White | 169 | 128 | 44.8 | Non-smoker | Moderate | Rheumatoid Arthritis | Cardiovascular Disease | leflunomide | Surgical intervention; Dietary counseling | 2024-02-29 | Placebo | null | null | Responder | Other | {"CRP": 34.8, "ESR": 48, "RF": 117, "Hemoglobin": 13.1, "WBC": 7.0} | Patient tolerating Placebo well with Responder noted at week 12; monitoring labs closely. |
PT0067 | 55 | Female | Black | 169 | 111 | 38.9 | Non-smoker | Moderate | Asthma | GERD; Obesity; Allergic Rhinitis | fluticasone; albuterol; salmeterol | Previous pharmacotherapy | 2023-08-10 | Placebo | null | null | Non-responder | Adverse Event | {"FEV1_pct": 91, "FVC": 5.5, "FeNO": 59, "Eosinophils": 1.47, "IgE": 183} | No adverse events reported; labs within normal range at most recent visit. |
PT0068 | 48 | Male | White | 167 | 107 | 38.4 | Non-smoker | null | Heart Failure | Chronic Kidney Disease; Anemia | furosemide | Surgical intervention | 2022-10-03 | Placebo | null | null | Partial Responder | Completed | {"BNP": 1413, "Creatinine": 1.94, "Sodium": 129, "Potassium": 5.8, "EF_pct": 31} | Referred back to primary care physician following no adverse events; study participation ended. |
PT0069 | 63 | Male | White | 168 | 113 | 40 | Former | Moderate | Hypothyroidism | Obesity; Hyperlipidemia; Anemia | levothyroxine; liothyronine | Dietary counseling; Previous pharmacotherapy | 2023-01-20 | Placebo | Weight Loss | Moderate | Responder | Completed | {"TSH": 39.28, "Free_T4": 0.54, "LDL": 130, "Hemoglobin": 9.6, "CK": 99} | Patient compliant with study medication; Responder at week 8 assessment. |
PT0070 | 64 | Other | Hispanic | 162 | 127 | 48.4 | Non-smoker | Moderate | Major Depressive Disorder | null | escitalopram | Dietary counseling; Previous pharmacotherapy | 2023-11-30 | Low Dose | null | null | Non-responder | Completed | {"TSH": 5.06, "Sodium": 134, "Vitamin_D": 37, "CBC_WBC": 10.9, "ALT": 48} | Patient experiencing no adverse events; dose held pending investigator review. |
PT0071 | 80 | Female | Black | 169 | 110 | 38.5 | Current | null | Major Depressive Disorder | null | mirtazapine; venlafaxine | Lifestyle modification; Previous pharmacotherapy | 2022-06-28 | Active Comparator | null | null | Partial Responder | Completed | {"TSH": 5.88, "Sodium": 141, "Vitamin_D": 42, "CBC_WBC": 5.2, "ALT": 58} | Stable on current regimen; Partial Responder confirmed at 6-month follow-up. |
PT0072 | 32 | Male | White | 178 | 90 | 28.4 | Non-smoker | Moderate | COPD | Depression | azithromycin; roflumilast; fluticasone | Lifestyle modification; Physical therapy | 2023-11-29 | Placebo | null | null | Non-responder | Completed | {"FEV1_pct": 40, "SpO2": 87, "PaCO2": 67, "CRP": 27.5, "Hemoglobin": 12.7} | No adverse events reported; labs within normal range at most recent visit. |
PT0073 | 51 | Female | Black | 162 | 81 | 30.9 | Non-smoker | null | Epilepsy | Cognitive Impairment; Sleep Disorder | topiramate | Previous pharmacotherapy | 2022-12-16 | High Dose | null | null | Non-responder | Completed | {"Drug_Level": 59.1, "ALT": 79, "CBC_WBC": 6.0, "Sodium": 140, "Hemoglobin": 14.7} | Stable on current regimen; Non-responder confirmed at 6-month follow-up. |
PT0074 | 28 | Male | White | 178 | 133 | 42 | Non-smoker | Moderate | Rheumatoid Arthritis | Anemia | prednisone; hydroxychloroquine; methotrexate | Surgical intervention; Physical therapy | 2022-05-12 | Placebo | null | null | Non-responder | Completed | {"CRP": 5.0, "ESR": 57, "RF": 251, "Hemoglobin": 9.1, "WBC": 10.1} | Patient tolerating Placebo well with Non-responder noted at week 12; monitoring labs closely. |
PT0075 | 38 | Female | White | 180 | 111 | 34.3 | Former | Moderate | Hypothyroidism | Obesity; Cardiovascular Disease | levothyroxine | Surgical intervention; Physical therapy | 2024-01-01 | High Dose | null | null | Responder | Lost to Follow-up | {"TSH": 23.51, "Free_T4": 0.82, "LDL": 109, "Hemoglobin": 14.0, "CK": 253} | Referred back to primary care physician following no adverse events; study participation ended. |
No dataset card yet
- Downloads last month
- 7